Cumberland PharmaceuticalsCPIX
About: Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
Employees: 91
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
9,800% more call options, than puts
Call options by funds: $297K | Put options by funds: $3K
67% more capital invested
Capital invested by funds: $2.61M [Q3] → $4.36M (+$1.75M) [Q4]
1.38% less ownership
Funds ownership: 14.5% [Q3] → 13.12% (-1.38%) [Q4]
9% less funds holding
Funds holding: 22 [Q3] → 20 (-2) [Q4]
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
67% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 9
Research analyst outlook
We haven’t received any recent analyst ratings for CPIX.
Financial journalist opinion
Based on 4 articles about CPIX published over the past 30 days
